MX2020000190A - Métodos para tratar la insuficiencia cardíaca con activadores de sarcómero cardíaco. - Google Patents

Métodos para tratar la insuficiencia cardíaca con activadores de sarcómero cardíaco.

Info

Publication number
MX2020000190A
MX2020000190A MX2020000190A MX2020000190A MX2020000190A MX 2020000190 A MX2020000190 A MX 2020000190A MX 2020000190 A MX2020000190 A MX 2020000190A MX 2020000190 A MX2020000190 A MX 2020000190A MX 2020000190 A MX2020000190 A MX 2020000190A
Authority
MX
Mexico
Prior art keywords
methods
heart failure
activators
treating heart
cardiac sarcomere
Prior art date
Application number
MX2020000190A
Other languages
English (en)
Inventor
Narimon Honarpour
Malik Fady
Original Assignee
Amgen Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Amgen Inc filed Critical Amgen Inc
Publication of MX2020000190A publication Critical patent/MX2020000190A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure

Landscapes

  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Cardiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Hospice & Palliative Care (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Physiology (AREA)
  • Nutrition Science (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Se proporcionan en el presente documento métodos para tratar a un sujeto con insuficiencia cardíaca, que comprende administrar al sujeto una dosis inicial de un activador de sarcómero cardíaco (CSA) durante un periodo de tiempo inicial, y administrar posteriormente al sujeto una dosis del CSA basada en la concentración en plasma del sujeto del CSA al final del periodo de tiempo inicial.
MX2020000190A 2017-06-30 2018-06-29 Métodos para tratar la insuficiencia cardíaca con activadores de sarcómero cardíaco. MX2020000190A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201762527983P 2017-06-30 2017-06-30
PCT/US2018/040181 WO2019006235A1 (en) 2017-06-30 2018-06-29 METHODS OF TREATING CARDIAC INSUFFICIENCY WITH CARDIAC SARCOMER ACTIVATORS

Publications (1)

Publication Number Publication Date
MX2020000190A true MX2020000190A (es) 2020-07-22

Family

ID=63013097

Family Applications (2)

Application Number Title Priority Date Filing Date
MX2020000190A MX2020000190A (es) 2017-06-30 2018-06-29 Métodos para tratar la insuficiencia cardíaca con activadores de sarcómero cardíaco.
MX2022015115A MX2022015115A (es) 2017-06-30 2020-01-08 Metodos para tratar la insuficiencia cardiaca con activadores de sarcomeros cardiacos.

Family Applications After (1)

Application Number Title Priority Date Filing Date
MX2022015115A MX2022015115A (es) 2017-06-30 2020-01-08 Metodos para tratar la insuficiencia cardiaca con activadores de sarcomeros cardiacos.

Country Status (10)

Country Link
US (3) US11576910B2 (es)
EP (1) EP3645002A1 (es)
JP (2) JP2020526483A (es)
CN (1) CN110996953A (es)
AU (2) AU2018290983B2 (es)
BR (1) BR112019028046A2 (es)
CA (1) CA3068588A1 (es)
MA (1) MA49508A (es)
MX (2) MX2020000190A (es)
WO (1) WO2019006235A1 (es)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EA031185B1 (ru) 2013-03-14 2018-11-30 Эмджен Инк. Гетероциклические соединения и способы их применения
SI3645518T1 (sl) 2017-06-30 2021-11-30 Amgen Inc. Sinteza omekamtiv mekarbila
MX2020000190A (es) 2017-06-30 2020-07-22 Amgen Inc Métodos para tratar la insuficiencia cardíaca con activadores de sarcómero cardíaco.
AU2019321573A1 (en) 2018-08-17 2021-03-04 Amgen Inc. Salts and crystal forms of omecamtiv mecarbil
CA3200673A1 (en) * 2020-11-12 2022-05-19 Amgen Inc. Methods of treating heart failure by administering omecamtiv mecarbil
CA3212491A1 (en) 2021-03-10 2022-09-15 Sebastien Caille Synthesis of omecamtiv mecarbil
WO2023164452A2 (en) * 2022-02-22 2023-08-31 Yale University Methods of treating, ameliorating, or preventing heart failure, and methods of promoting heart muscle growth
WO2024081611A1 (en) * 2022-10-11 2024-04-18 Cytokinetics, Incorporated Methods for treating heart failure by administering cardiac sarcomere activators
US11986474B1 (en) 2023-06-27 2024-05-21 Cytokinetics, Incorporated Methods for treating heart failure by administering cardiac sarcomere activators

Family Cites Families (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4450150A (en) 1973-05-17 1984-05-22 Arthur D. Little, Inc. Biodegradable, implantable drug delivery depots, and method for preparing and using the same
AU2546399A (en) 1998-02-10 1999-08-30 Yoshitomi Pharmaceutical Industries, Ltd. Preparations with controlled release
GB2344287A (en) 1998-12-03 2000-06-07 Ferring Bv Controlled release pharmaceutical formulation
EP1551505B1 (en) 2002-10-04 2010-02-24 Microchips, Inc. Medical device for controlled drug delivery and cardiac monitoring and/or stimulation
EP2862859B1 (en) 2004-06-17 2018-07-25 Cytokinetics, Inc. Compounds, compositions and methods
AR058347A1 (es) 2005-12-15 2008-01-30 Cytokinetics Inc Entidades quimias composiciones y metodos
JP2009537530A (ja) 2006-05-15 2009-10-29 ウィスコンシン・アルムニ・リサーチ・ファウンデーション １α，２５−ジヒドロキシビタミンＤ３の肺送達および副甲状腺ホルモンまたはカルシトニンの同時投与
FR2902092B1 (fr) 2006-06-07 2008-09-05 Sapelem Soc Par Actions Simpli Appareil de manutention de charge
CN101657190B (zh) 2007-04-19 2013-09-11 东亚制药株式会社 一种适用于对葡萄糖控制肽进行控释的可生物降解的微球组合物及其制剂
EA031185B1 (ru) 2013-03-14 2018-11-30 Эмджен Инк. Гетероциклические соединения и способы их применения
JP6634368B2 (ja) * 2013-03-14 2020-01-22 アムジエン・インコーポレーテツド 複素環式化合物及びそれらの使用
US20180022710A1 (en) 2015-01-29 2018-01-25 Signal Pharmaceuticals, Llc Isotopologues of 2-(tert-butylamino)-4-((1r,3r,4r)-3-hydroxy-4-methylcyclohexylamino)-pyrimidine-5-carboxamide
AU2016282985B2 (en) 2015-06-26 2021-07-29 Amgen Inc. Combination therapy of cardiac myosin activator and sinus node if current inhibitor
SI3645518T1 (sl) 2017-06-30 2021-11-30 Amgen Inc. Sinteza omekamtiv mekarbila
MX2020000190A (es) 2017-06-30 2020-07-22 Amgen Inc Métodos para tratar la insuficiencia cardíaca con activadores de sarcómero cardíaco.
LT3594199T (lt) 2018-07-09 2020-11-10 F.I.S.- Fabbrica Italiana Sintetici S.P.A. Kristalinis 2-fluor-3-nitroluenas ir jo paruošimo būdas
WO2020014406A1 (en) 2018-07-12 2020-01-16 Assia Chemical Industries Ltd. Solid state forms of omecamtiv mecarbil & omecamtiv mecarbil dihcl
AU2019321573A1 (en) 2018-08-17 2021-03-04 Amgen Inc. Salts and crystal forms of omecamtiv mecarbil
WO2020131574A1 (en) 2018-12-18 2020-06-25 Amgen Inc. Method of reducing aromatic nitro compounds
US20220340542A1 (en) 2019-09-19 2022-10-27 Synthon B.V. Salts of omecamtiv mecarbil and solid forms thereof
WO2021053175A1 (en) 2019-09-19 2021-03-25 Synthon B.V. Salts of omecamtiv mecarbil and solid forms thereof
US20220411374A1 (en) 2019-10-09 2022-12-29 Dr. Reddy's Laboratories Limited Alternate processes for the preparation of omecamtiv mecarbil
EP4041198A4 (en) 2019-10-09 2023-08-16 Dr. Reddy's Laboratories Limited SOLID FORMS OF OMECAMTIV MECARBIL DIHYDROCHLORIDE AND PROCESS THEREOF
WO2021136477A1 (zh) 2020-01-03 2021-07-08 苏州科睿思制药有限公司 化合物i二盐酸盐的共晶及其制备方法和用途
CN115279349A (zh) 2020-02-10 2022-11-01 安进股份有限公司 奥美卡替莫卡必尔片剂
CA3200673A1 (en) 2020-11-12 2022-05-19 Amgen Inc. Methods of treating heart failure by administering omecamtiv mecarbil
CA3212491A1 (en) 2021-03-10 2022-09-15 Sebastien Caille Synthesis of omecamtiv mecarbil
WO2023205291A2 (en) 2022-04-21 2023-10-26 The Board Of Regents Of The University Of Oklahoma Targeting myocardial tissue for delivery of therapeutic and imaging agents

Also Published As

Publication number Publication date
US11931358B2 (en) 2024-03-19
JP2020526483A (ja) 2020-08-31
US20200155547A1 (en) 2020-05-21
CA3068588A1 (en) 2019-01-03
MX2022015115A (es) 2023-01-18
EP3645002A1 (en) 2020-05-06
MA49508A (fr) 2020-05-06
AU2024200991A1 (en) 2024-03-07
US11576910B2 (en) 2023-02-14
US20230149394A1 (en) 2023-05-18
AU2018290983B2 (en) 2023-11-23
WO2019006235A1 (en) 2019-01-03
JP2023088944A (ja) 2023-06-27
CN110996953A (zh) 2020-04-10
US20230355615A1 (en) 2023-11-09
AU2018290983A1 (en) 2020-01-23
BR112019028046A2 (pt) 2020-07-07

Similar Documents

Publication Publication Date Title
MX2022015115A (es) Metodos para tratar la insuficiencia cardiaca con activadores de sarcomeros cardiacos.
EP4252833A3 (en) Microstimulation sleep disordered breathing (sdb) therapy device
MX2018005588A (es) Terapia de sustitucion de plasminogeno para la deficiencia de plasminogeno.
PH12017502103A1 (en) Methods and kits for treating depression
MX2018013354A (es) Terapia de combinacion para tratamiento de cancer.
MX2022008868A (es) Tratamiento del cancer con tg02.
WO2019006005A3 (en) METHODS AND COMPOSITIONS FOR THE TREATMENT OF MELANOMA
MX2023012450A (es) Esketamina para el tratamiento de la depresion.
MX2020013557A (es) Un esteroide de c21-pirazolilo disustituido con 19-nor c3,3 y métodos de uso del mismo.
AU2018341571A8 (en) Therapeutic methods relating to HSP90 inhibitors
WO2019090347A8 (en) Adenosine pathway inhibitors for cancer treatment
PH12019502316A1 (en) Combination cancer immunotheraphy with pentaaza macrocyclic ring complex
TW201613592A (en) Glucose metabolism ameliorating agent
MX2017016347A (es) Terapia de combinacion de activador de miosina cardiaca e inhibidor de corriente if del nodo sinusal.
MX2016009102A (es) Composiciones de enolasa 1 (eno1) y sus usos.
WO2018217710A8 (en) Micro-nanobubble solutions for tissue preservation and generation thereof
TW201613544A (en) Treatment device and chair
EP4252847A3 (en) Regimens and methods of treating multiple sclerosis using ofatumumab
TW201613639A (en) Methods for treating cardiovascular diseases
MX2020003243A (es) Métodos para tratar la insuficiencia cardíaca con fracción de eyección preservada.
MX2017009313A (es) Formulaciones intravenosas de baclofeno y metodos de tratamiento.
MX2020008905A (es) Usos terapeuticos de activadores de glucoquinasa en combinacion con insulina o analogos de insulinas.
EA201592058A1 (ru) Применение ландиолола гидрохлорида в длительном лечении тахиаритмии
PH12017501918A1 (en) Multi-peptide composition
SG10201809418VA (en) New administration routes of insulin, insulin analogs or derivatives of insulin